Ananda Pharma PLC's (AQSE:ANA) CEO, Melissa Sturgess, is on Friday presenting at a private investor event hosted by Talman House in Zurich. The UK-based biopharmaceutical company is developing regulatory-approved cannabinoid medicines for chronic conditions.
Ananda is currently advancing four confirmed clinical trials. The company is among a select group presenting to Talman House members, a network focused on cannabis and related industries.